2 results
Approved WMOCompleted
The primary study objective is to assess the effect of lanreotideAutogel 120mg administered every 28 days compared to placebo, onprogression-free survival in patients with well or moderatelydifferentiated non functioning entero-pancreatic endocrine…
Approved WMOCompleted
Primary objective:To assess the clinical activity of AL101 using radiographic assessments and RECIST v1.1 in ACC patients with activating Notchmutations.Secundary objectives:• To assess quality of life in ACC patients with activating mutations.• To…